Grants and Contributions:

Back to search

Title:

Pre-clinical and Clinical Development for LSALT Peptide to Treat Inflammation and Kidney Injury

Agreement Number:

919337

Agreement Value:

$200,000.00

Agreement Date:

Jan 1, 2019 - Jan 29, 2021

Description:

LSALT is a peptide drug and a selective non-enzymatic dipeptidase-1 antagonist and prevents leukocyte adhesion to endothelial cells creating numerous indications for targeting inflammation in the context of microbial and non-microbial (sterile) tissue injury. In pre-clinical mouse models, LSALT has proven efficacious in preventing acute kidney injury induced by ischemia-reperfusion, toxins and sepsis. LSALT patents have been assigned to Arch Biopartners Inc. who will manage drug development and human clinical trials for acute kidney injury as the first indication. Identification of new and more effective versions of LSALT is ongoing.

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Toronto, Ontario, CA M4T 2M5

Reference Number:

172-2018-2019-Q4-919337

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

101328227

Recipient Type:

For-profit organization

Additional Information:

This agreement has been amended 1 time(s). The end date of this agreements has been modified by 182 days.

Amendment Date

Oct 29, 2020

Recipient's Legal Name:

Arch Biopartners Inc.

Federal Riding Name:

Toronto--St. Paul's

Federal Riding Number:

35090

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

334512

Amendments:

See Amendments